Sentences with phrase «european vaccine research»

The European Commission (EC), in the context of the Horizon 2020 Framework Programme, commits significant funding to TRANSVAC2, a European vaccine research and development (R&D) infrastructure.

Using a bottom - up approach, the needs and priorities regarding European vaccine R&D were identified through a series of stakeholder consultations and workshops, and translated into a proposal for the establishment of a European Vaccine Research & Development Infrastructure (EVRI).

In order to facilitate access to these skills and capacities, and to promote collaborations in the European vaccine landscape - aiming thereby to accelerate the development of safe, effective and affordable vaccines - the EC, in the context of the Horizon 2020 Framework Programme, has recently funded «TRANSVAC2», a European vaccine research and development (R&D) infrastructure.

Not exact matches

The European research collaboration behind this study focuses on deep immunological analysis of the immunogenicity and reactogenicity of the Ebola vaccine in healthy volunteers.

The European VSV - EBOVAC project is a multidisciplinary research collaboration which brings together 13 leading international vaccine research institutes from six EU countries and the USA.

This work, published in the scientific journal Nature Medicine, was carried out in collaboration with researchers at the Scripps Research Institute in La Jolla and the Center for infectious disease research in Seattle and was partially funded by the Swiss National Science Foundation (SNSF), the European Research Council (ERC), Swiss Vaccine Research Institute and the Fondazione Aldo e CelResearch Institute in La Jolla and the Center for infectious disease research in Seattle and was partially funded by the Swiss National Science Foundation (SNSF), the European Research Council (ERC), Swiss Vaccine Research Institute and the Fondazione Aldo e Celresearch in Seattle and was partially funded by the Swiss National Science Foundation (SNSF), the European Research Council (ERC), Swiss Vaccine Research Institute and the Fondazione Aldo e CelResearch Council (ERC), Swiss Vaccine Research Institute and the Fondazione Aldo e CelResearch Institute and the Fondazione Aldo e Cele Daccò.

Funding: This work was supported by the European Commission sixth Frame Work Programme as part of the European Vaccines and Microbicides Enterprise (EUROPRISE), the European Commission seventh Frame Work Programme as part of the Combined Highly Active Anti-retroviral Microbicides project (CHAARM)[to RAW], the Bill and Melinda Gates Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD grant 38637 [to RAW] and grant 1032144 [to MSS]-RRB-, and the UK Medical Research Council [RAW and AF].

TRANSVAC2 builds upon the success of TRANSVAC, the European Network of Vaccine Research and Development funded under the EC's previous Framework Programme (FP7).

Nanotheraputics for Antibiotic Resistent Emerging Bacterial pathogens (NAREB) European Research Infrastructures for Poverty Related Diseases (EURIPED) Biomarkers for enhanced vaccines immunosafety (BioVacSafe) European network of vaccine research and development TRANSVAC Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBResearch Infrastructures for Poverty Related Diseases (EURIPED) Biomarkers for enhanced vaccines immunosafety (BioVacSafe) European network of vaccine research and development TRANSVAC Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBresearch and development TRANSVAC Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Geels M, Thøgersen RL, Guzman CA, Ho MM, Verreck F, Collin N, Robertson JS, McConkey SJ, Kaufmann SH, Leroy O. TRANSVAC research infrastructure - Results and lessons learned from the European network of vaccine research and development.

In its first funding period, which commenced in 2009 and was completed in 2013, TRANSVAC made a significant contribution to the support of individual European scientific groups through the provision of state - of - the - art vaccine experimental services, technical training, and innovative vaccine research and development (R&D).

Furthermore, over thirty scientists received specialised training on numerous aspects of vaccine development, being provided with a thorough overview of the full vaccine development process, and more than twenty innovative scientific papers were published from TRANSVAC's research and activities (for more information see also tables below and: Geels, M. et al (2015): TRANSVAC research infrastructure — Results and lessons learned from the European network of vaccine research and development.

TRANSVAC is a new infrastructure project - funded by the European Commission in the context of Horizon 2020 - that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges with the ultimate goal to build an efficient and sustainable collaboration of experts and facilities to catalyse vaccine research in Europe.

But the American and European research communities didn't regard randomized field trials as essential until the 1950s, when Jonas Salk discovered the polio vaccine and Sen. Estes Kefauver held hearings on the testing of thalidomide and other drugs.